OR WAIT 15 SECS
© 2021 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
December 09, 2020
If telehealth is here to stay, how is the industry adjusting?
December 03, 2020
Mitigating the risks of development, authorization, and marketing for new therapies following "new normal" created by COVID-related violations.
August 31, 2020
Ferdi Steinmann outlines a few supply chain lessons that all pharma companies can learn from the COVID-19 pandemic.
July 01, 2020
Taking stock of evolving practices in protecting the supply chain amid the pandemic, including partnering and planning for what’s next.
March 18, 2020
It is vital to begin asking questions about your company’s DSCSA readiness and compliance, as well as that of your strategic partners, writes Rob Besse.
March 12, 2020
MilliporeSigma's Robert McGuirk speaks with Pharma Exec about the role of supply chain robustness in helping to mitigate the risk of drug shortages
October 08, 2019
Coexisting with the DSCSA may hinder new legislative efforts.
August 08, 2019
How to navigate the production and reimbursement intricacies of bringing regenerative medicines from bench to bedside.
February 08, 2019
Tim Willis and Oliver Wack outline the role of alternative data in supply chain risk management, and the ancillary benefits that come from adopting such technology.
January 23, 2019
Pharm Exec’s annual look at what lies ahead for the biopharma industry in the coming months examines eight key trends that are seemingly at tipping points in their evolution and poised to shape the life sciences landscape in 2019.